PDE1C Protein, Human (sf9, His-GST)

PDE1C, a member of the phosphodiesterase (PDE) family, is a subtype of PDE activated by Ca²⁺.PDE1 plays an important role in the cardiovascular system.PDE inhibitors can reduce neuroinflammation and oxidative stress, stimulate neuroplasticity, and improve symptoms of mental disorders in preclinical models by activating the CAMP-PGKA-CREB and cGMP-PKG pathways.PDE1C Protein, Human (sf9, His-GST) is the recombinant human-derived PDE1C protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

Phosphodiesterase (PDE) is an enzyme that breaks phosphodiester bonds, usually ring nucleotide phosphodiesterase. Phosphodiesterases consist of a group of enzymes that degrade the phosphodiester bonds in the second messenger molecule cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signals within subcellular domains. PDE inhibitors can reduce neuroinflammation and oxidative stress, stimulate neuroplasticity, and improve symptoms of mental disorders in preclinical models by activating the CAMP-PGKA-CREB and cGMP-PKG pathways. PDE1 is composed of three isomers: PDE1A, PDE1B and PDE1C. PDE1 is the only known subtype of PDE activated by Ca²⁺. PDE1 plays an important role in the cardiovascular system^[1][2][3].

Human

Sf9 insect cells

N-His;N-GST

Q8TAE4 (M1-E634)

/

Full Length

MESPTKEIEEFESNSLKYLQPEQIEKIWLRLRGLRKYKKTSQRLRSLVKQLERGEASVVDLKKNLEYAATVLESVYIDETRRLLDTEDELSDIQSDAVPSEVRDWLASTFTRQMGMMLRRSDEKPRFKSIVHAVQAGIFVERMYRRTSNMVGLSYPPAVIEALKDVDKWSFDVFSLNEASGDHALKFIFYELLTRYDLISRFKIPISALVSFVEALEVGYSKHKNPYHNLMHAADVTQTVHYLLYKTGVANWLTELEIFAIIFSAAIHDYEHTGTTNNFHIQTRSDPAILYNDRSVLENHHLSAAYRLLQDDEEMNILINLSKDDWREFRTLVIEMVMATDMSCHFQQIKAMKTALQQPEAIEKPKALSLMLHTADISHPAKAWDLHHRWTMSLLEEFFRQGDREAELGLPFSPLCDRKSTMVAQSQVGFIDFIVEPTFTVLTDMTEKIVSPLIDETSQTGGTGQRRSSLNSISSSDAKRSGVKTSGSEGSAPINNSVISVDYKSFKATWTEVVHINRERWRAKVPKEEKAKKEAEEKARMAAEEQQKEMEAKSQAEEGASGKAEKKTSGETKNQVNGTRANKSDNPRGKNSKAEKSSGEQQQNGDFKDGKNKTDKKDHSNIGNDSKKTDDSQE

Approximately 97 kDa,based on SDS-PAGE under reducing conditions.

≥ 85%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.